{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:29:25Z","timestamp":1789475365113,"version":"build-2803163510"},"reference-count":58,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Heart failure with preserved ejection fraction (HFpEF) is a complex and heterogeneous clinical syndrome characterized by signs and symptoms of heart failure despite normal or near-normal ejection fraction. It is a debilitating chronic disease that affects millions of people worldwide, and due to the paucity of evidence-based pharmacological treatments for HFpEF, nonpharmacological approaches as potential therapeutic alternatives are of growing interest. As a result, renal denervation (RDN), initially developed as a therapeutic tool for resistant hypertension, has become an area of active clinical interest. RDN is a catheter-based procedure that targets the renal sympathetic pathways, aiming to reduce neurohormonal activation and mitigate maladaptive cardiac remodeling. Preclinical studies in animal models have demonstrated that RDN can improve cardiac and vascular fibrosis, reduce renal inflammation, control hypertension, and alleviate endothelial dysfunction. Recent clinical studies have further highlighted the potential benefits of RDN in patients with HFpEF and uncontrolled hypertension. In this review, we aim to outline the pathophysiology of HFpEF and demonstrate the complex clinical interplay involved in how RDN impacts the heart. Moreover, we discuss the present status of clinical studies on RDN and explore its therapeutic potential as a viable treatment for HFpEF.<\/jats:p>","DOI":"10.3390\/jcm14124115","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T12:53:16Z","timestamp":1749559996000},"page":"4115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Renal Denervation in HFpEF"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0346-0718","authenticated-orcid":false,"given":"Dawood","family":"Jamil","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Henry Ford Hospital, Detroit, MI 48202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-294X","authenticated-orcid":false,"given":"Sanaullah","family":"Mojaddedi","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Central Florida, Graduate Medical Education, Orlando, FL 32827, USA"},{"name":"Internal Medicine Residency Program, HCA Florida North Florida Hospital, Gainesville, FL 32605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kollman","sequence":"additional","affiliation":[{"name":"School of Medicine, Wayne State University, Detroit, MI 48202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeebullah","family":"Bangash","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Corewell Health Dearborn Hospital, Dearborn, MI 48124, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Sami","family":"Abdelhai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Henry Ford Hospital, Detroit, MI 48202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8146-256X","authenticated-orcid":false,"given":"Yazeed","family":"Aburuman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saint Michael\u2019s Medical Center, Newark, NJ 07102, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir S.","family":"Lotfi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Baystate Medical Center, Springfield, MA 01199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart Failure with Preserved Ejection Fraction: A Review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"key":"ref_2","unstructured":"Golla, M.S.G., and Shams, P. (2025, March 23). Heart Failure With Preserved Ejection Fraction (HFpEF), StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK599960\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e05","DOI":"10.15420\/cfr.2023.13","article-title":"The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment","volume":"10","author":"Balestrieri","year":"2024","journal-title":"Card. Fail. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11897-013-0155-7","article-title":"The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction","volume":"10","author":"Oktay","year":"2013","journal-title":"Curr. Heart Fail Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.hfc.2014.04.003","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"10","author":"Andersson","year":"2014","journal-title":"Heart Fail Clin."},{"key":"ref_6","first-page":"1","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Andersson","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/CIRCRESAHA.115.302922","article-title":"Heart failure with preserved ejection fraction: Mechanisms, clinical features, and therapies","volume":"115","author":"Sharma","year":"2014","journal-title":"Circ. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart Failure with Preserved Ejection Fraction: JACC Scientific Statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Januzzi","year":"2023","journal-title":"J. Am. Coll Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial","volume":"131","author":"Probstfield","year":"2015","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e011269","DOI":"10.1161\/CIRCHEARTFAILURE.123.011269","article-title":"Nonpharmacological Approaches to Managing Heart Failure With Preserved Ejection Fraction","volume":"17","author":"Tang","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.iccl.2017.03.013","article-title":"Renal Denervation to Modify Hypertension and the Heart Failure State","volume":"6","author":"Zhong","year":"2017","journal-title":"Intervent. Cardiol. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1038\/s41440-024-01801-9","article-title":"Differences in the effectiveness and safety of different renal denervation devices","volume":"47","author":"Ogoyama","year":"2024","journal-title":"Hypertens. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1053\/j.ajkd.2022.03.015","article-title":"Renal Denervation: A Review","volume":"80","author":"Townsend","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_16","unstructured":"(2025, March 03). Renal Denervation for the Treatment of Hypertension: A Scientific Statement from the American Heart Association|Hypertension. Available online: https:\/\/www.ahajournals.org\/doi\/10.1161\/HYP.0000000000000240."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A Controlled Trial of Renal Denervation for Resistant Hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","article-title":"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): A randomised, sham-controlled, proof-of-concept trial","volume":"390","author":"Townsend","year":"2017","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): A multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","article-title":"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): A randomised, multicentre, single-blind, sham-controlled trial","volume":"397","author":"Azizi","year":"2021","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.4244\/EIJ-D-23-00088","article-title":"Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications","volume":"19","author":"Pathak","year":"2023","journal-title":"EuroIntervention"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e034910","DOI":"10.1161\/JAHA.124.034910","article-title":"Randomized Trials of Renal Denervation for Uncontrolled Hypertension: An Updated Meta-Analysis","volume":"13","author":"Mufarrih","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_24","unstructured":"(2025, March 03). Efficacy and Safety of Sympathetic Mapping and Ablation of Renal Nerves for the Treatment of Hypertension (SMART): 6-Month Follow-Up of a Randomised, Controlled Trial\u2014eClinicalMedicine. Available online: https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(24)00205-0\/fulltext."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1540-8159.2004.00431.x","article-title":"Heart Rate Variability and Diastolic Heart Failure","volume":"27","author":"Arora","year":"2004","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/cvr\/cvab222","article-title":"Central and peripheral sympathetic activation in heart failure","volume":"118","author":"Grassi","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jacbts.2021.11.007","article-title":"Characterization of Cardiac Sympathetic Nervous System and Inflammatory Activation in HFpEF Patients","volume":"7","author":"Kaye","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cardfail.2019.02.014","article-title":"Characterization of Sympathetic Innervation in Heart Failure with Preserved Ejection Fraction","volume":"25","author":"Fang","year":"2019","journal-title":"J. Card. Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1001\/jama.288.17.2144","article-title":"Pathophysiological Characterization of Isolated Diastolic Heart Failure in Comparison to Systolic Heart Failure","volume":"288","author":"Kitzman","year":"2002","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10741-024-10456-0","article-title":"The sympathetic nervous system in heart failure with preserved ejection fraction","volume":"30","author":"Chang","year":"2025","journal-title":"Heart Fail. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1916598","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jchf.2015.10.008","article-title":"Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial","volume":"4","author":"Edelmann","year":"2016","journal-title":"JACC Heart Fail."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jchf.2023.09.007","article-title":"Contemporary Use and Implications of Beta-Blockers in Patients with HFmrEF or HFpEF","volume":"12","author":"Peikert","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102376","DOI":"10.1016\/j.cpcardiol.2024.102376","article-title":"Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis","volume":"49","author":"Kaddoura","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Smarz, K., Tysarowski, M., Zaborska, B., Pilichowska-Paszkiet, E., Sikora-Frac, M., Budaj, A., and Jaxa-Chamiec, T. (2021). Chronotropic Incompetence Limits Aerobic Exercise Capacity in Patients Taking Beta-Blockers: Real-Life Observation of Consecutive Patients. Healthcare, 9.","DOI":"10.3390\/healthcare9020212"},{"key":"ref_37","unstructured":"(2025, April 11). Renal Denervation in the Setting of Heart Failure|Heart Failure Reviews. Available online: https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10489-z."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ejhf.1788","article-title":"Quality of life in heart failure with preserved ejection fraction: Importance of obesity, functional capacity, and physical inactivity","volume":"22","author":"Reddy","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jchf.2018.02.006","article-title":"Comparing Measures to Assess Health-Related Quality of Life in Heart Failure with Preserved Ejection Fraction","volume":"6","author":"Napier","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ejhf.502","article-title":"Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): A randomized controlled trial","volume":"18","author":"Patel","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E007421","DOI":"10.1161\/CIRCHEARTFAILURE.120.007421","article-title":"Renal Sympathetic Denervation in Patients with Heart Failure With Preserved Ejection Fraction","volume":"14","author":"Kresoja","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"E010543","DOI":"10.1161\/CIRCHEARTFAILURE.123.010543","article-title":"Modulation of Pulsatile Left Ventricular Afterload by Renal Denervation in Heart Failure with Preserved Ejection Fraction","volume":"16","author":"Rommel","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_43","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Alcidi, G., Goffredo, G., Correale, M., Brunetti, N.D., and Iacoviello, M. (2022). Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure. J. Clin. Med., 11.","DOI":"10.3390\/jcm11113192"},{"key":"ref_45","unstructured":"(2024, December 13). Utility and Validity of the HFA-PEFF and H2FPEF Scores in Patients with Symptomatic Atrial Fibrillation, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/38520461\/."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"(2024, December 13). Prognosis and NT-proBNP in Heart Failure Patients with Preserved Versus Reduced Ejection Fraction | Heart. Available online: https:\/\/heart.bmj.com\/content\/105\/15\/1182.","DOI":"10.1136\/heartjnl-2018-314173"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Vogt, A., Plehn, A., Atti, C., Nussbaum, M., Tongers, J., Sedding, D., and Dutzmann, J. (2024). Left ventricular structure and function following renal sympathetic denervation in patients with HFpEF: An echocardiographic 9-year long-term follow-up. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1408547"},{"key":"ref_49","first-page":"15","article-title":"Hypertension and heart failure with preserved ejection fraction: Connecting the dots","volume":"16","author":"Tsioufis","year":"2018","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kassab, K., Soni, R., Kassier, A., and Fischell, T.A. (2022). The Potential Role of Renal Denervation in the Management of Heart Failure. J. Clin. Med., 11.","DOI":"10.3390\/jcm11144147"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehz746.0237","article-title":"Renal denervation improves diastolic dysfunction in patients with HFpEF\u2014Initial results of a multicenter CMR study","volume":"40","author":"Zamani","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart Failure with Reduced Ejection Fraction: A Review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Koufou, E.-E., Arfaras-Melainis, A., Rawal, S., and Kalogeropoulos, A.P. (2021). Treatment of Heart Failure with Mid-Range Ejection Fraction: What Is the Evidence. J. Clin. Med., 10.","DOI":"10.3390\/jcm10020203"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00392-020-01633-w","article-title":"Therapeutic approaches in heart failure with preserved ejection fraction: Past, present, and future","volume":"109","author":"Wintrich","year":"2020","journal-title":"Clin. Res. Cardiol."},{"key":"ref_57","first-page":"94","article-title":"SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?","volume":"2014","author":"Patel","year":"2014","journal-title":"Glob. Cardiol. Sci. Pr."},{"key":"ref_58","unstructured":"Barbato, E., Azizi, M., Schmieder, R., Lauder, L., B\u00f6hm, M., Brouwers, S., Bruno, R.M., Dudek, D., Kahan, T., and Kandzari, D. (2025, March 04). Renal Denervation in the Management of Hypertension in Adults. A Clinical Consensus Statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Available online: https:\/\/eurointervention.pcronline.com\/article\/renal-denervation-in-the-management-of-hypertension-in-adults-a-clinical-consensus-statement-of-the-esc-council-on-hypertension-and-the-european-association-of-percutaneous-cardiovascular-interventions-eapci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/12\/4115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:49:40Z","timestamp":1760032180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/12\/4115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["jcm14124115"],"URL":"https:\/\/doi.org\/10.3390\/jcm14124115","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}